CStone considering sale, says report

18 July 2022
cstone_large

Chinese biotech firm CStone Pharmaceuticals' (HKEX: 2616) is mulling over a potential sale of the business, according to sources cited by Bloomberg.

CStone is exploring strategic options for the future of the enterprise and has drafted in investment bank Goldman Sachs to sound out interest from prospective buyers, the report states.

Bloomberg does not name the sources due to their preference to remain anonymous, but they believe that acquiring CStone could be of interest to other Chinese or global pharma companies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology